多拉米特:一种新型治疗非转移去势抵抗性前列腺癌的药物  

Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer

作　　者：张帆(综述)[1] 卢一平(审校)[1] ZHANG Fan;LU Yi-ping(Department of Urology,West China Hospital of Sichuan University,Chendu,Sichuan 610041,China)

机构地区：[1]四川大学华西医院泌尿外科,四川成都610041

出　　处：《中华男科学杂志》2020年第4期364-368,共5页National Journal of Andrology

摘　　要：前列腺癌是男性最常见的肿瘤之一。接受雄激素剥夺疗法(ADT)后仍出现PSA的升高或影像学的进展,被称为去势抵抗性前列腺癌(CRPC)。CRPC根据是否有影像学的转移又可分为转移去势抵抗性前列腺癌(mCRPC)和非转移去势抵抗性前列腺癌(nmCRPC)两种类型。2018年有两项二代抗雄激素药物(恩杂鲁胺和阿帕鲁胺)获得批准用于治疗nmCRPC。最新完成的3期大型临床ARAMIS试验表明,一种新型药物多拉米特(Darolutamide)相比安慰剂能够延长nmCRPC患者的无转移生存期(MFS)。多拉米特有望成为治疗nmCRPC患者的第3种二代抗雄激素药物。本综述将回顾多拉米特的临床试验,并比较多拉米特和其他两项二代抗雄激素药物的治疗效果。Prostate cancer(PCa) is one of the most common tumors in male. Castration-resistant PCa(CRPC) refers to the prostate malignancy with a PSA increase or imaging progression after androgen-deprivation therapy(ADT), which is divided into metastatic CRPC(mCRPC) and non-metastatic CRPC(nmCRPC) based on the presence or absence of imaging metastasis. Two second-generation antiandrogens, enzuramide and abiraterone, were approved for the treatment of nmCRPC in 2018. A recently completed three-stage large-scale clinical ARAMIS trial shows that the new drug, darolutamide, compared with the placebo, could prolong the metastasis-free survival(MFS) of nmCRPC patients. Darolutamide is now an anti-androgen drug available for patients with nmCRPC. This review focuses on the clinical trial of darolutamide and comparison of its therapeutic effect with that of another two second-generation antiandrogens.

关 键 词：前列腺癌 雄激素剥夺疗法 Darolutamide ODM-201 

分 类 号：R737.25[医药卫生—肿瘤]